Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.79 - $13.53
Previous CloseN/A
Volume320.41K
Average Volume (3M)2.24M
Market Cap
$2.92B
Enterprise Value$3.45B
Total Cash (Recent Filing)$213.75M
Total Debt (Recent Filing)$443.64M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
May 07, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding307,239,840
10 Day Avg. Volume2,774,437
30 Day Avg. Volume2,241,484
Standard Deviation0.14
R-Squared0.05
Alpha0.00403
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.39
Price to Cash Flow (P/CF)-181.80
P/FCF Ratio102.10
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.26
Enterprise Value/Ebitda117.36
Forecast
1Y Price Target
$16.56Price Target Upside74.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Amicus News
PremiumCompany Announcements
Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes
PremiumCompany Announcements
Amicus Therapeutics Shines with Strong Earnings Call---
Bulls Say, Bears Say
Bulls Say
Market ExpansionManagement continues to focus on the naive population and geographic/label expansion for Galafold.
Regulatory ApprovalsThe therapy was recently approved in Australia, two additional regulatory approvals are expected in 2025 (Japan and Canada), and up to 10 launch countries are expected this year.
Bears Say
Patient AdditionsThe number of patients on treatment implies a plateauing of patient additions, which is not surprising given no new launch countries in recent quarters combined with the holiday season.
---
Ownership Overview
1.37% Insiders
32.30% Mutual Funds
38.07% Other Institutional Investors
11.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $8.79 and its highest was $13.53 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $2.92B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 64 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Feb 19, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.038.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is -0.05.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 307,239,840 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of $0.05 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went down -2.944%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
---
Amicus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.56 (74.50% Upside)
$16.56 (74.50% Upside)
Blogger Sentiment
Bullish
FOLD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $79.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.71%
12-Months-Change
Fundamentals
Return on Equity
-31.68%
Trailing 12-Months
Asset Growth
0.92%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
FOLD Company Deck
---
FOLD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amicus Therapeutics reported strong financial and operational performance with significant revenue growth driven by successful product launches and strategic market expansion. Despite currency exchange rate exposures and regulatory complexities, the company's outlook remains positive with targets for continued revenue growth and improved profitability.Read More>---
FOLD Stock 12 Month Forecast
Average Price Target
$16.56
▲(74.50% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering FOLD
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+26.26%
reiterated a buy rating 4 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.26% per trade.
---